Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)

Funding Agency:
National Institutes of Health

The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry to the Development stage, to advance a single development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Alternatively, projects can enter at the Development stage and progress in a shorter period to IND enabling toxicology studies and phase I clinical testing. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.

Companion FOA:  

PAR-20-111, U44 Small Business Innovation Research (SBIR) Cooperative Agreement - Fast-Track


  • Letter of Intent Due Date(s): 30 days prior to the application due date 
  • Application Due Date(s): August 11, 2020, February 9, 2021, August 10, 2021, February 9, 2022 August 9, 2022, February 9, 2023​; Aug. 9, 2023
  • AIDS Application Due Date(s): September 7, 2020, May 7, 2021, September 7, 2021, May 7, 2022, September 7, 2022, May 7 2023​; Sep. 7, 2023

PAR-20-122 Expiration Date new date September 8, 2023 per NOT-NS-22-098

Agency Website

Amount Description

Application budgets are not limited but need to reflect the actual needs of the proposed project.

 Applicants may seek up to one year of UG3 funding. The UH3 phase cannot exceed four years. The actual duration of individual projects will depend on successful achievement of milestones and conditions as described in Milestones Section of the program overview.

Funding Type





Environmental & Life Sciences
Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

August 9, 2023